Outcomes & treatment options for patients with AML who relapse after alloHSCT

Outcomes & treatment options for patients with AML who relapse after alloHSCTПодробнее

Poor outcomes of patients with AML who relapse underscores the need for effective initial treatmentПодробнее

Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapseПодробнее

Best of ASH 2019Подробнее

Indications for allogeneic stem cell transplantation in AMLПодробнее

Debate: Hodgkin lymphoma patient who relapses after autologous SCT - Allogeneic SCTПодробнее

The outcomes of intensive treatment for patients with AML who have failed venetoclax-based therapyПодробнее

AML Indications for Transplantation and Treatment of RelapseПодробнее

Management of relapse following alloHSCT in patients with AML and MDSПодробнее

Prevention, detection and treatment of AML relapse after allo-SCTПодробнее

AML relapse after HSCT: trends and predictive factorsПодробнее

Managing ALL patients who relapse after transplantationПодробнее

Managing post-transplant relapse in AMLПодробнее

Predictors of outcomes in post-transplant patients with AMLПодробнее

Talking Post-Transplant Acute Myeloid Leukemia - Improving Outcomes after RelapseПодробнее

Single-center study evaluating the outcomes of patients with AML who relapsed after alloSCTПодробнее

Advances in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (AML)Подробнее

Outcomes of alloHSCT in TP53-mutated AML and MDSПодробнее

Why do patients relapse after transplant? #AMLПодробнее

Optimizing transplantation outcomes for patients with AMLПодробнее

Outcomes with RIC before second HSCT in secondary AMLПодробнее

How can we improve outcomes after allo-HSCT in patients with AML?Подробнее

Transplantation outcomes in patients with secondary AMLПодробнее